GALE Share Price

Open 0.34 Change Price %
High 0.34 1 Day -0.02 -5.88
Low 0.32 1 Week -0.04 -11.11
Close 0.32 1 Month -0.26 -44.83
Volume 358941 1 Year -0.12 -27.27
52 Week High 4.75
52 Week Low 0.16
GALE Important Levels
Resistance 2 0.34
Resistance 1 0.33
Pivot 0.33
Support 1 0.31
Support 2 0.30
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DCTH 0.13 -13.33%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
ARCI 1.45 137.70%
FALC 0.40 60.00%
AMCF 0.03 50.00%
LOCM 0.09 50.00%
OPXAW 0.10 42.86%
VRTA 4.50 38.46%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
ATRM 1.70 21.43%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PTSX 0.05 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Galena Biopharma, Inc. (NASDAQ: GALE)

GALE Technical Analysis 5
As on 21st Aug 2017 GALE Share Price closed @ 0.32 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.96 & Strong Sell for SHORT-TERM with Stoploss of 0.53 we also expect STOCK to react on Following IMPORTANT LEVELS.
GALE Target for August
1st Target up-side 0.63
2nd Target up-side 0.67
3rd Target up-side 0.71
1st Target down-side 0.53
2nd Target down-side 0.49
3rd Target down-side 0.45
GALE Other Details
Segment EQ
Market Capital 139060160.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.galenabiopharma.com
GALE Address
GALE
4640 SW Macadam Avenue
Suite 270
Portland, OR 97239
United States
Phone: 855-855-4253
GALE Latest News
Interactive Technical Analysis Chart Galena Biopharma, Inc. ( GALE NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Galena Biopharma, Inc.
GALE Business Profile
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). In January 2014, Galena Biopharma Inc acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.